CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Study to Evaluate the Safety and Efficacy of the MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05720052
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:22.114404+00:00
Published At: 2024-07-18T00:00:00+00:00
Record Updated At: 2024-07-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Relapsed or Refractory B-cell Lymphoma", "Diffuse Large B-cell Lymphoma (DLBCL)", "Follicular Lymphoma (FL)", "Mantle Cell Lymphoma (MCL)", "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)", "Marginal Zone Lymphoma (MZL)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-07-18"
protocolSection.identificationModule.nctId: "NCT05720052"
protocolSection.identificationModule.officialTitle: "A Phase I/II Study to Evaluate the Safety and Efficacy of the MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.